Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

OBJECTIVE: To directly compare the efficacy of natalizumab and fingolimod in patients with active relapsing-remitting multiple sclerosis. METHODS: This phase 4, randomised, rater- and sponsor-blinded, prospective, parallel-group, clinic-based head-to-head study was conducted at 43 sites in nine coun...

Descripción completa

Detalles Bibliográficos
Autores principales: Butzkueven, Helmut, Licata, Stephanie, Jeffery, Douglas, Arnold, Douglas L, Filippi, Massimo, Geurts, Jeroen JG, Santra, Sourav, Campbell, Nolan, Ho, Pei-Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577060/
https://www.ncbi.nlm.nih.gov/pubmed/33082194
http://dx.doi.org/10.1136/bmjopen-2020-038861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577060/
https://www.ncbi.nlm.nih.gov/pubmed/33082194
http://dx.doi.org/10.1136/bmjopen-2020-038861

Ejemplares similares